Comparative Efficacy of SSRIs and Amisulpride in Burning Mouth Syndrome

Maina, Giuseppe; Vitalucci, Alberto; Gandolfo, S; Bogetto, Filippo

doi:10.4088/jcp.v63n0108

Cited by 119 publications

(114 citation statements)

References 0 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…The communication of different therapeutic measures to control the BMS is wide in the world literature (11)(12)(13)(14)(15)(16)(17)(18)(19)(20). The Gabapentin was used by White et al (15) in a case of a patient with BMS obtaining healing of the case and it was subsequently used by Heckmann et al (16) who conducted a study with gabapentin in 15 patients, where the initial dose was 300 mg / day and then grew at a rate of 300 mg every 48 hours to a maximum of 2400 mg / day.…”

Section: Discussionmentioning

confidence: 99%

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

López-D'alessandro¹,

Escovich²

2011

Med Oral

100

180

View full text Add to dashboard Cite

Burning Mouth Syndrome (BMS) is a disease that manifests as burning in the tongue or in any area of the oral mucosa, in the absence of clinically verifiable injuries. Objectives: To verify the efficacy of alpha lipoic acid (ALA) and gabapentin (GABA), used individually and jointly, to reduce the burning in patients with burning mouth and establish a drug therapy for the BMS. Study Design: During April and May 2008, we conducted a randomized, double-blind, placebo-controlled trial in the Department of Clinical Stomatology, Faculty of Dentistry, Rosario, Argentina. The gathering of patients was between those ones with BMS who were treated in our service between March 2003 and March 2008 without complying with the applied treatments. The 120 patients were randomly divided into 4 groups and were provided, by lot and in a blinded fashion, with four different treatment cycles consisting of the following drugs: Group A (n = 20) 600 mg / day of alpha lipoic acid for two months, Group B (n = 20) 300 mg / day of gabapentin for two months, Group C (n = 20) a combination of both drugs for two months and Group D (n = 60) 100 mg / day of cellulose starch for two months (control group). Results and Conclusions: All 120 patients completed the treatment. The best response was obtained with the combination of ALA + GABA, with a 70% of the cases with reduced burning in this group and a 13.2 times greater chance of presenting positive changes for these patients than those taking placebo. The combined use of drugs that act at different levels of the nociceptive system can be useful for the treatment of this syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

López-D'alessandro¹,

Escovich²

2011

Med Oral

100

180

View full text Add to dashboard Cite

show abstract

“…50,54,56,[97][98][99][100][101][102] Five studies comparing SSRIs with placebo have found them to be superior to placebo for relieving neuropathic pain. 50,[103][104][105][106] In fibromyalgia, fluoxetine (ES: 1.08) is reported to have greater analgesic activity than citalopram (ES: 0.45) and paroxetine (ES: 0.19).…”

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

Efficacy of Antidepressants as Analgesics: A Review

Dharmshaktu¹,

Tayal²,

Kalra³

2012

The Journal of Clinical Pharma

274

189

View full text Add to dashboard Cite

Persistent pain disorders are usually not adequately alleviated by nonsteroidal anti‐inflammatory drugs or other simple analgesics. Use of antidepressants as adjuvant therapy for the control of persistent pain is currently being practiced in disorders such as fibromyalgia, neuropathic pain, rheumatoid conditions, low back pain, and headache. This review describes the various mechanisms of analgesic activity of antidepressants along with their efficacy and tolerability profiles. Meta‐analyses and clinical studies of these agents were retrieved through the use of MEDLINE, Google scholar, and Cochrane databases. Antidepressants are effective in both neuropathic and non‐neuropathic pain and have diverse mechanisms independent of their antidepressant effects. Tricyclic antidepressants (amitryptiline, nortryptiline, desipramine) are effective compounds in the treatment of neuropathic pain, fibromyalgia, low back pain, and headaches. Studies are ongoing for the dual serotonin norepinephrine reuptake inhibitors (duloxetine, venlafaxine) in several persistent pain conditions and these may be recommended in neuropathic pain, migraines, and fibromyalgia. Evidence suggests that although the analgesic effects of selective serotonin reuptake inhibitors (fluoxetine, paroxetine, citalopram) are limited and inconsistent, yet they have a superior tolerability profile compared with tricyclic antidepressants.

show abstract

“…11) Paroxetine and amisulpride are equally effective for pain reduction in short-term treatment. 12) Results pertaining to the therapeutic effect of alpha-lipoic acid are mixed and inconclusive. Some studies 13,14) reported improvement, while others [15][16][17] failed to demonstrate effectiveness over placebo.…”

Section: Discussionmentioning

confidence: 99%

Retrospective Review of Effectiveness of Various Pharmacological Agents in Treating Burning Mouth Syndrome

Im¹,

Kim²,

Kim³

2016

Journal of Oral Medicine and Pain

View full text Add to dashboard Cite

Purpose: Burning mouth syndrome (BMS) is a chronic pain condition involving the oral and perioral regions, often characterized by a burning sensation and pain in elderly patients. In this study, we investigated the effectiveness of pharmacological agents for the treatment of BMS patients through a retrospective chart review. Methods:We enrolled 61 BMS subjects (57 females, 4 males; 66.4±10.9 years of age) from among consecutive patients treated pharmacologically from January 2014 to June 2015 at Chonnam National University Dental Hospital. Patients with secondary BMS associated with local factors were excluded. The treatment period, number of pharmacological agents tried, and effectiveness of the drugs administered to each subject were analyzed. Results:The mean treatment period for the management of BMS was 2.5 months. More than three agents were tried to control BMS symptoms in 17 subjects (27.9%); two agents were used in 10 subjects (16.4%), and a single agent in 24 subjects (39.3%). Clonazepam was prescribed most frequently and was effective at relieving symptoms in 30 of 39 subjects (76.9%). Paroxetine was moderately effective, relieving symptoms in 7 of 17 subjects (41.2%). Some of the subjects benefited from tricyclic antidepressants, gabapentin, and lipoic acid. A topical local anesthetic used to supplement other systemic agents had ameliorating effects in four of six subjects. Conclusions:Within the study limitations, clonazepam was the most effective drug and antidepressants were efficacious in some subjects for relieving the symptoms of BMS. These pharmacological agents could be considered as first-line drugs for the management of BMS.

show abstract

Comparative Efficacy of SSRIs and Amisulpride in Burning Mouth Syndrome

Cited by 119 publications

References 0 publications

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial

Efficacy of Antidepressants as Analgesics: A Review

Retrospective Review of Effectiveness of Various Pharmacological Agents in Treating Burning Mouth Syndrome

Contact Info

Product

Resources

About